Brian M Casey1, Elizabeth A Thom1, Alan M Peaceman1, Michael W Varner1, Yoram Sorokin1, Deborah G Hirtz1, Uma M Reddy1, Ronald J Wapner1, John M Thorp1, George Saade1, Alan T N Tita1, Dwight J Rouse1, Baha Sibai1, Jay D Iams1, Brian M Mercer1, Jorge Tolosa1, Steve N Caritis1, J Peter VanDorsten1. 1. From the University of Texas Southwestern Medical Center, Dallas (B.M.C.), the University of Texas Medical Branch, Galveston (G.S.), and the University of Texas Health Science Center at Houston, McGovern Medical School-Children's Memorial Hermann Hospital, Houston (B.S.) - all in Texas; George Washington University Biostatistics Center, Washington, DC (E.A.T.); Northwestern University, Chicago (A.M.P.); the University of Utah Health Sciences Center, Salt Lake City (M.W.V.); Wayne State University, Detroit (Y.S.); the National Institute of Neurological Disorders and Stroke (D.G.H.) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.M.R.), Bethesda, MD; Columbia University, New York (R.J.W.); the University of North Carolina at Chapel Hill, Chapel Hill (J.M.T.); the University of Alabama at Birmingham, Birmingham (A.T.N.T.); Brown University, Providence, RI (D.J.R.); Ohio State University, Columbus (J.D.I.), and MetroHealth Medical Center-Case Western Reserve University, Cleveland (B.M.M.) - both in Ohio; Oregon Health and Science University, Portland (J.T.); University of Pittsburgh, Pittsburgh (S.N.C.); and the Medical University of South Carolina, Charleston (J.P.V.).
Abstract
BACKGROUND:Subclinical thyroid disease during pregnancy may be associated with adverse outcomes, including a lower-than-normal IQ in offspring. It is unknown whether levothyroxine treatment of women who are identified as having subclinical hypothyroidism or hypothyroxinemia during pregnancy improves cognitive function in their children. METHODS: We screened women with a singleton pregnancy before 20 weeks of gestation for subclinical hypothyroidism, defined as a thyrotropin level of 4.00 mU or more per liter and a normal free thyroxine (T4) level (0.86 to 1.90 ng per deciliter [11 to 24 pmol per liter]), and for hypothyroxinemia, defined as a normal thyrotropin level (0.08 to 3.99 mU per liter) and a low free T4 level (<0.86 ng per deciliter). In separate trials for the two conditions, women were randomly assigned to receive levothyroxine or placebo. Thyroid function was assessed monthly, and the levothyroxine dose was adjusted to attain a normal thyrotropin or free T4 level (depending on the trial), with sham adjustments for placebo. Children underwent annual developmental and behavioral testing for 5 years. The primary outcome was the IQ score at 5 years of age (or at 3 years of age if the 5-year examination was missing) or death at an age of less than 3 years. RESULTS: A total of 677 women with subclinical hypothyroidism underwent randomization at a mean of 16.7 weeks of gestation, and 526 with hypothyroxinemia at a mean of 17.8 weeks of gestation. In the subclinical hypothyroidism trial, the median IQ score of the children was 97 (95% confidence interval [CI], 94 to 99) in the levothyroxine group and 94 (95% CI, 92 to 96) in the placebo group (P=0.71). In the hypothyroxinemia trial, the median IQ score was 94 (95% CI, 91 to 95) in the levothyroxine group and 91 (95% CI, 89 to 93) in the placebo group (P=0.30). In each trial, IQ scores were missing for 4% of the children. There were no significant between-group differences in either trial in any other neurocognitive or pregnancy outcomes or in the incidence of adverse events, which was low in both groups. CONCLUSIONS: Treatment for subclinical hypothyroidism or hypothyroxinemia beginning between 8 and 20 weeks of gestation did not result in significantly better cognitive outcomes in children through 5 years of age than no treatment for those conditions. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov number, NCT00388297 .).
RCT Entities:
BACKGROUND:Subclinical thyroid disease during pregnancy may be associated with adverse outcomes, including a lower-than-normal IQ in offspring. It is unknown whether levothyroxine treatment of women who are identified as having subclinical hypothyroidism or hypothyroxinemia during pregnancy improves cognitive function in their children. METHODS: We screened women with a singleton pregnancy before 20 weeks of gestation for subclinical hypothyroidism, defined as a thyrotropin level of 4.00 mU or more per liter and a normal free thyroxine (T4) level (0.86 to 1.90 ng per deciliter [11 to 24 pmol per liter]), and for hypothyroxinemia, defined as a normal thyrotropin level (0.08 to 3.99 mU per liter) and a low free T4 level (<0.86 ng per deciliter). In separate trials for the two conditions, women were randomly assigned to receive levothyroxine or placebo. Thyroid function was assessed monthly, and the levothyroxine dose was adjusted to attain a normal thyrotropin or free T4 level (depending on the trial), with sham adjustments for placebo. Children underwent annual developmental and behavioral testing for 5 years. The primary outcome was the IQ score at 5 years of age (or at 3 years of age if the 5-year examination was missing) or death at an age of less than 3 years. RESULTS: A total of 677 women with subclinical hypothyroidism underwent randomization at a mean of 16.7 weeks of gestation, and 526 with hypothyroxinemia at a mean of 17.8 weeks of gestation. In the subclinical hypothyroidism trial, the median IQ score of the children was 97 (95% confidence interval [CI], 94 to 99) in the levothyroxine group and 94 (95% CI, 92 to 96) in the placebo group (P=0.71). In the hypothyroxinemia trial, the median IQ score was 94 (95% CI, 91 to 95) in the levothyroxine group and 91 (95% CI, 89 to 93) in the placebo group (P=0.30). In each trial, IQ scores were missing for 4% of the children. There were no significant between-group differences in either trial in any other neurocognitive or pregnancy outcomes or in the incidence of adverse events, which was low in both groups. CONCLUSIONS: Treatment for subclinical hypothyroidism or hypothyroxinemia beginning between 8 and 20 weeks of gestation did not result in significantly better cognitive outcomes in children through 5 years of age than no treatment for those conditions. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov number, NCT00388297 .).
Authors: Karen L Wilson; Brian M Casey; Donald D McIntire; Lisa M Halvorson; F Gary Cunningham Journal: Obstet Gynecol Date: 2012-02 Impact factor: 7.661
Authors: V J Pop; J L Kuijpens; A L van Baar; G Verkerk; M M van Son; J J de Vijlder; T Vulsma; W M Wiersinga; H A Drexhage; H L Vader Journal: Clin Endocrinol (Oxf) Date: 1999-02 Impact factor: 3.478
Authors: Brian M Casey; Jodi S Dashe; C Edward Wells; Donald D McIntire; William Byrd; Kenneth J Leveno; F Gary Cunningham Journal: Obstet Gynecol Date: 2005-02 Impact factor: 7.661
Authors: Marcos Abalovich; Nobuyuki Amino; Linda A Barbour; Rhoda H Cobin; Leslie J De Groot; Daniel Glinoer; Susan J Mandel; Alex Stagnaro-Green Journal: J Clin Endocrinol Metab Date: 2007-08 Impact factor: 5.958
Authors: Michelle A Kominiarek; Marcela C Smid; Lisa Mele; Brian M Casey; Yoram Sorokin; Uma M Reddy; Ronald J Wapner; John M Thorp; George R Saade; Alan T N Tita; Dwight J Rouse; Baha Sibai; Jay D Iams; Brian M Mercer; Jorge Tolosa; Steve N Caritis Journal: Obstet Gynecol Date: 2018-12 Impact factor: 7.661
Authors: T I M Korevaar; Arash Derakhshan; Peter N Taylor; Marcel Meima; Liangmiao Chen; Sofie Bliddal; David M Carty; Margreet Meems; Bijay Vaidya; Beverley Shields; Farkhanda Ghafoor; Polina V Popova; Lorena Mosso; Emily Oken; Eila Suvanto; Aya Hisada; Jun Yoshinaga; Suzanne J Brown; Judit Bassols; Juha Auvinen; Wichor M Bramer; Abel López-Bermejo; Colin Dayan; Laura Boucai; Marina Vafeiadi; Elena N Grineva; Alexandra S Tkachuck; Victor J M Pop; T G Vrijkotte; M Guxens; L Chatzi; J Sunyer; A Jiménez-Zabala; I Riaño; M Murcia; X Lu; S Mukhtar; C Delles; U Feldt-Rasmussen; S M Nelson; E K Alexander; L Chaker; T Männistö; J P Walsh; E N Pearce; E A P Steegers; R P Peeters Journal: JAMA Date: 2019-08-20 Impact factor: 56.272
Authors: Jamil M Kazma; John van den Anker; Karel Allegaert; André Dallmann; Homa K Ahmadzia Journal: J Pharmacokinet Pharmacodyn Date: 2020-02-06 Impact factor: 2.745
Authors: Spyridoula Maraka; Raphael Mwangi; Xiaoxi Yao; Lindsey R Sangaralingham; Naykky M Singh Ospina; Derek T O'Keeffe; Rene Rodriguez-Gutierrez; Marius N Stan; Juan P Brito; Victor M Montori; Rozalina G McCoy Journal: J Clin Endocrinol Metab Date: 2019-04-24 Impact factor: 5.958
Authors: Jennifer M Yamamoto; Amy Metcalfe; Kara A Nerenberg; Rshmi Khurana; Alex Chin; Lois E Donovan Journal: CMAJ Date: 2020-06-01 Impact factor: 8.262